Inside that determined head, his brain cells were dying.
In the quiet deterioration of a man once defined by vigor and competitive spirit, a rare and nameless enemy revealed itself too late — Progressive Supranuclear Palsy, a disease that dismantles the brain's most essential functions while medicine stands largely without answer. Affecting only five in every 100,000 Australians, PSP occupies the difficult space between obscurity and devastation, misread as dementia, undetected for years, and unchecked by any cure or diagnostic test. It is a condition that forces us to reckon with the limits of medical knowledge and the particular cruelty of diseases too rare to command the attention they deserve. Yet in laboratories at Monash University, researchers are pressing forward — targeting the toxic proteins at the heart of the disease, and holding open the possibility that understanding may yet arrive in time to matter.
- A man who walked with the stride of someone half his age was silenced within three years — not by dementia, as his family feared, but by a disease most doctors will never encounter in their careers.
- PSP mimics dementia so convincingly that Joseph Micallef spent two and a half years on the wrong medications before a fill-in doctor finally recognised the pattern — a delay that is not the exception but the norm.
- The disease's rarity creates a self-reinforcing trap: too few patients to attract funding, too little funding to build awareness, and too little awareness to catch it before it has already taken hold.
- Swallowing fails, vision doubles, eyelids freeze, and patients fall — the body's most basic functions unravel in sequence, with aspiration pneumonia waiting at the end of the road.
- At Monash University, researchers are testing tau-targeting drugs and building biobanks of patient data, with clinical results expected within two years — a measured but genuine movement toward answers.
- Roughly 1,200 Australians are living with PSP right now, supported by little government funding and almost no public awareness, their families navigating a diagnosis that arrives late and offers nothing in return.
Joseph Micallef was a man of routine and vigour — morning walks, afternoon bocce, a sharpness that belied his age. The first signs of something wrong arrived during the pandemic: he mistook neighbours' houses for his own, fell asleep standing at the kitchen table, developed strange new food preferences, and began laughing in ways that didn't suit him. His family suspected dementia. What was actually happening, invisibly, was far rarer.
For two and a half years, doctors treated him for dementia. Medications changed repeatedly and nothing worked. It took a locum doctor — filling in while his regular GP was on maternity leave — to recognise the true pattern: Progressive Supranuclear Palsy, a neurodegenerative disorder affecting only five in every 100,000 Australians. PSP damages the brain regions governing movement, balance, vision, and swallowing. It strikes people over sixty, progresses over five to eight years, and arrives without genetic warning signs, without a diagnostic test, and without a cure.
By early 2023, Joseph was in a nursing home — unable to speak, unable to walk, dependent on others for every meal. Neurologist Professor Simon Lewis explains that swallowing difficulties and aspiration pneumonia are often how the disease ends. For Joseph, it ended in October 2023. His decline had been so swift that his family was left holding questions medicine could not answer.
His story is not unusual. A general practitioner may encounter PSP once in an entire career. Patients cycle through specialists until someone recognises the constellation of symptoms, which presents differently in almost every case. The disease's rarity creates a vicious cycle — too few patients to attract funding, too little funding to develop treatments or awareness, and no early-warning system to catch it before significant damage is done. Governments classify such conditions as orphan diseases, rare enough to be overlooked.
Research is nonetheless moving forward. At Monash University, scientists are trialling a medication administered via lumbar puncture to around 300 patients worldwide, with results expected within two years. A separate drug targeting tau — the toxic protein that accumulates and clumps in PSP patients' brains — is being developed using sodium selenite to reduce its stickiness and slow further damage. A biobank of blood samples and brain scans from PSP patients is also being built, allowing researchers to track the disease's progression and revisit promising treatments at scale.
Australia has roughly 1,200 people living with PSP. The road toward understanding remains long, but researchers say awareness is as important as funding — and that patients and families need not navigate it alone. Support is available through Fight Parkinson's, which runs bimonthly online groups for those affected by the disease.
Joseph Micallef was the kind of man who made his grandchildren work to keep up. In his seventies, he walked his dog each morning with the stride of someone half his age, and most afternoons found him at the bocce court, where his competitive instincts never dulled. He was fit, sharp, the picture of someone who had earned his vigor through decades of living well. What nobody could see was that inside his skull, his brain was quietly dying.
The first signs arrived during the pandemic, subtle enough that they might have been dismissed as the ordinary slowing of age. On walks, he would sometimes mistake a neighbor's house for his own. He'd nod off at the kitchen table before lunch, his eyes closing for hours at a time, even while standing. His appetite changed in ways that seemed almost comical at first—he developed a taste for prawns and yogurt, foods he had once dismissed as rubbish. But the symptom that truly unsettled his family was the laughter. Joseph was a serious man, and sudden outbursts of hilarity didn't fit the person they knew. His family braced for dementia; his mother's side carried that history. Instead, within three years, the man who had argued politics over lunch became completely silent, confined to a wheelchair, able to communicate only by squeezing a hand.
For two and a half years, doctors treated him for dementia. The medications changed repeatedly. Nothing worked. It wasn't until a replacement doctor—filling in while his regular physician was on maternity leave—recognized the pattern. Joseph had Progressive Supranuclear Palsy, a neurodegenerative disorder so rare that it affects only five in every 100,000 Australians. The disease damages the brain regions controlling movement, balance, vision, and swallowing. It typically strikes people over sixty and progresses over five to eight years, though some cases move faster than others. There is no cure. There is no diagnostic test. Researchers still don't understand why it happens.
By February 2023, Joseph was in a nursing home, unable to speak or walk, dependent on others to spoon-feed him. Professor Simon Lewis, a neurologist who researches neurodegenerative conditions, explained that swallowing difficulties are often how the disease announces itself—double vision that makes no sense, eyelids that stick, food going down the wrong pipe. Patients fall and fracture bones. They develop aspiration pneumonia. That's frequently how it ends. For Joseph, it ended in October 2023, after a brutal bout with pneumonia. His decline had been so rapid that his family was left with more questions than answers.
Joseph wasn't the first person to be misdiagnosed, and he won't be the last. A general practitioner might encounter PSP once in an entire career. There is no clear diagnostic test. Patients shuttle between specialists until someone recognizes the constellation of symptoms. The disease presents differently in different people, rarely matching the textbook description. Worse, there are no genetic markers, no predisposing factors that might alert doctors to watch for it. It arrives without warning and without a way to catch it early. This rarity creates a vicious cycle: because the disease is rare, it attracts little funding; because it attracts little funding, researchers struggle to develop treatments or diagnostic tools; because there are no treatments or tools, awareness remains low. Governments classify such conditions as "orphan diseases"—rare enough to seem boutique, too rare to justify investment.
But research is underway. At Monash University, scientists are testing a medication designed to alter the disease's course, administered through lumbar puncture to about 300 patients worldwide, with results expected within two years. The university is also developing its own drug, funded by the Medical Research Future Fund, targeting tau—a toxic protein that accumulates in the brains of PSP patients. When tau builds up, it becomes sticky, forming clumps that damage neural function. Associate Professor Lucy Vivash is working to reduce tau's stickiness using sodium selenite, preventing further accumulation. The university has also established a biobank of blood samples and brain scans from PSP patients, allowing researchers to track how the disease evolves and to retest promising treatments on large groups of people who have already contributed their data.
Dr. Kelly Bertram, a clinical neurologist specializing in movement disorders, acknowledged the long road ahead. Understanding the condition itself remains incomplete, and clinical trial options need to expand globally. Raising awareness matters as much as funding does—the disease receives little media attention and little government support, despite leaving people profoundly disabled. There are roughly 1,200 PSP patients in Australia. The journey has been slow, but researchers say they must keep going and hope. Patients and families can reach out to researchers directly or seek support through Fight Parkinson's, which hosts bimonthly online groups for people living with PSP.
Notable Quotes
A general practitioner would potentially see it once in their entire career, and there's no clear diagnostic test—patients often go through multiple specialists before someone recognizes it.— Professor Simon Lewis, neurologist
It's a disease that doesn't get much media attention and often doesn't get a lot of funding attention either, despite people being quite disabled by it.— Dr. Kelly Bertram, clinical neurologist
The Hearth Conversation Another angle on the story
Why did it take so long to diagnose your grandfather? What made PSP so easy to mistake for dementia?
The symptoms overlap almost completely at first—memory problems, personality changes, difficulty with balance. Dementia is common; PSP is not. A doctor sees the obvious pattern and treats for that. It wasn't until someone with specific knowledge of rare neurological conditions looked at him that the real diagnosis emerged.
And by then, two and a half years had passed.
Yes. Two and a half years of medications that did nothing, of watching him decline without understanding why. If we'd known earlier, we might have enrolled him in one of the trials happening now. We might have had options.
The researchers talk about tau protein accumulating in the brain. Can you explain what that means in practical terms?
It's like a toxic buildup—imagine plaque forming inside the pipes of a house, gradually blocking the flow. Except these pipes are neurons, and the blockage is killing them. The brain regions that control movement, balance, vision—they all get choked off.
Your grandfather went from walking speedwalkers to being completely non-verbal in three years. That's extraordinarily fast.
Some cases move slower. His was aggressive. The pneumonia at the end—that's common. The swallowing problems mean food goes into the lungs instead of the stomach. The body can't fight it off.
What would have helped your family most during those years?
A diagnosis. Knowing what we were actually fighting. And knowing there were researchers working on it, that there might be a path forward. Instead, we felt like we were watching something we didn't understand destroy someone we loved.
Do you think the trials happening now will come in time for others?
I hope so. The researchers seem genuinely committed. But there are only about 1,200 people with PSP in all of Australia. It's hard to run large studies when your patient population is that small. It's hard to get funding when the disease is that rare. The system isn't built for diseases like this.